

REVIEW

# Recent advances in understanding the neonatal microbiome [version 1; peer review: 3 approved]

Matthew J. Dalby<sup>1\*</sup>, Lindsay J. Hall 1-3\*

<sup>1</sup>Gut Microbes and Health, Quadram Institute Bioscience, Norwich Research Park, Norwich, UK

<sup>2</sup>Intestinal Microbiome, School of Life Sciences, Technical University of Munich, Freising, Germany

<sup>3</sup>ZIEL – Institute for Food & Health, Technical University of Munich, Freising, Germany

\* Equal contributors

**v1** **First published:** 22 May 2020, 9(F1000 Faculty Rev):422  
<https://doi.org/10.12688/f1000research.22355.1>  
**Latest published:** 22 May 2020, 9(F1000 Faculty Rev):422  
<https://doi.org/10.12688/f1000research.22355.1>

**Abstract**

The neonatal developmental window represents a key time for establishment of the gut microbiota. First contact with these microbes within the infant gastrointestinal tract signifies the start of a critical mutualistic relationship, which is central for short- and longer-term health. Recent research has provided insights into the origin of these microbial pioneers, how they are maintained within the gut environment, and how factors such as antibiotics or preterm birth may disrupt the succession of beneficial microbes. The acquisition, colonisation, and maintenance of the early life microbiota, and subsequent interactions with the host is a rapidly developing research area. In this review we explore some of these key topics which have been illuminated by recent research, and we highlight some of the important unresolved questions which currently limit our overall understanding of the neonatal gut microbiome.

**Keywords**

neonatal, microbiome, gut, transmission, diet, antibiotics, preterm infants

**Open Peer Review**

**Reviewer Status**

	Invited Reviewers		
	1	2	3
<b>version 1</b> 22 May 2020			

**F1000 Faculty Reviews** are written by members of the prestigious **F1000 Faculty**. They are commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

- 1 **Avital Cher**, The Hebrew University of Jerusalem, Jerusalem, Israel  
**Moran Yassour**, The Hebrew University of Jerusalem, Jerusalem, Israel  
 The Hebrew University of Jerusalem, Jerusalem, Israel
- 2 **Susanne Brix Pedersen**, Technical University of Denmark, Kongens Lyngby, Denmark
- 3 **Omry Koren**, Bar-Ilan University, Safed, Israel

Any comments on the article can be found at the end of the article.

**Corresponding authors:** Matthew J. Dalby ([Matthew.Dalby@quadram.ac.uk](mailto:Matthew.Dalby@quadram.ac.uk)), Lindsay J. Hall ([Lindsay.Hall@quadram.ac.uk](mailto:Lindsay.Hall@quadram.ac.uk))

**Author roles:** **Dalby MJ:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Hall LJ:** Conceptualization, Funding Acquisition, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** This work was funded by a Wellcome Trust Investigator Award (no. 100/974/C/13/Z) and an Institute Strategic Programme Gut Microbes and Health grant no. BB/R012490/1 and its constituent projects BBS/E/F/000PR10353 and BBS/E/F/000PR10356 to L.J.H. *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2020 Dalby MJ and Hall LJ. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Dalby MJ and Hall LJ. **Recent advances in understanding the neonatal microbiome [version 1; peer review: 3 approved]** F1000Research 2020, 9(F1000 Faculty Rev):422 <https://doi.org/10.12688/f1000research.22355.1>

**First published:** 22 May 2020, 9(F1000 Faculty Rev):422 <https://doi.org/10.12688/f1000research.22355.1>

**Introduction**

The communities of microbes that inhabit the infant gut play numerous important roles across the early life developmental window that directly impacts neonatal health. The gut microbiota is involved in the programming and maturation of the immune system<sup>1</sup>, the use and modification of dietary nutrients, shaping the gut environment by producing metabolites as by-products of their metabolism<sup>2</sup>, and preventing colonisation of the gut by pathogens. The neonatal period after birth (which for this review we define as the first month after birth) is a crucial phase for the establishment of early life microbial pioneers, which helps establishment of the wider microbial community over time. Here we will focus on the infant gut, which represents the (to date) most studied microbiota site and the body niche harbouring the most diverse and dense microbial community.


Compared to the adult gut, the neonatal infant gut hosts a relatively uncomplicated community of bacteria, fungi, and viruses. Of these, bacteria have been the focus for many researchers, while the presence of fungi<sup>3</sup> and viruses<sup>4</sup> is only now receiving due attention, and the effects of their presence remain little explored compared to their bacterial neighbours<sup>5-8</sup>. From initial colonisation at birth, the infant acquires a community of microbes specialised at inhabiting the human gut, which evolves and changes through infancy and childhood. These changes occur

primarily in response to a changing nutritional environment, with other external factors such as antibiotics also significantly impacting community composition (Figure 1).

The bacterial genus *Bifidobacterium* is a “characteristic” member of the infant gut and typically dominates the microbiota in vaginally delivered, breastfed infants<sup>9</sup>. Specific species and strains of *Bifidobacterium* have evolved to selectively digest special sugars in breast milk. *Bifidobacterium* metabolise these sugars, producing various microbial fermentation products such as the short chain fatty acid acetate, which reduces pH, creating an acidic gut environment<sup>2</sup>, whilst also metabolising breast milk amino acids into aromatic lactic acid, which has emerging roles that include improving the integrity of the infant gut wall<sup>10</sup>. While the importance of the gut microbiota and its interactions with the infant are now clear, the ways in which an infant acquires their microbiota and the source of these microbes have until recently remained largely unknown.

**Origin of the neonatal microbiota**

The initial, and probably most important, contribution to the establishment of the infant microbiota is microbes from the infant’s mother, acquired by vertical transmission<sup>11</sup>. In the womb, developing infants remain largely isolated from exposure to microorganisms in the environment<sup>12</sup>. During and



**Factors influencing the development of the neonatal microbiota**

Sterile womb? Uncertain presence and relevance of microbes before birth	Maternal prophylactic antibiotics through umbilical cord	C-section vs. vaginal birth: disrupted transfer of (faecal) maternal bacteria	Premature vs. term birth: extensive antibiotic treatment and hospital environment	Formula vs. breastfeeding: lack of human milk oligosaccharides (HMOs) & breast milk microbes	Antibiotic treatment: loss of beneficial antibiotic-sensitive species	Transfer of bacteria from siblings and other family members
---	--	---	---	--	---	---

**Neonatal gut microbial signatures**

'Healthy' vs. 'disturbed'	Bacterial species & strains resemble those found in the mother's gut vs. bacterial species & strains resemble skin and hospital bacteria	<i>Bifidobacterium</i> and <i>Bacteroides</i> dominate – low bacterial diversity vs. Higher bacterial diversity – <i>Staphylococcus</i> , <i>Escherichia coli</i> , <i>Enterococcus</i> & <i>Klebsiella</i>	HMO-metabolising <i>Bifidobacterium</i> vs. simple sugar-metabolising bacterial strains such as <i>Escherichia coli</i> , & <i>Klebsiella</i>	<i>Bifidobacterium</i> -produced metabolites such as acetate – acidic environment vs. reduced short-chain fatty acids and more neutral environment
---------------------------	--	---	---	--

**Figure 1.** A summary of current understanding of factors influencing the establishment of the neonatal microbiota and the resulting microbial signatures of a “healthy” neonatal microbiota.

shortly after birth, the infant is rapidly exposed to microbes that may colonise transiently or may find a longer-term niche. The methods of delivery play a significant role in determining this initial ‘inoculation’. Studies have shown differences in microbial composition of the infant gut between those born by vaginal delivery and those born by caesarean delivery. Although previous research has been conflicting on its impact, recent larger pregnancy–infant cohort studies have shown that delivery method, either vaginal or caesarean birth, does result in a different gut microbial signature, highlighting the importance of the first microbes to which an infant is exposed<sup>13–15</sup>. Infants delivered by caesarean section appear to have disrupted transfer of *Bacteroides* and *Bifidobacterium* from the mother, with increased colonisation by opportunistic pathogens found in the hospital environment such as *Enterococcus*, *Enterobacter*, and *Klebsiella* species<sup>13</sup>. The “disturbed” microbiota associated with caesarean section has prompted some to attempt “vaginal seeding”<sup>16</sup>; this is the deliberate transfer of the vaginal microbiota to the newborn infant to promote the establishment of a “normal” infant microbiota. However, this practice has recently been called into question, as the vaginal microbiota is not similar to the microbiota that typically soon comes to dominate the infant gut, alongside the risk of group B streptococcus (GBS) transfer (see antibiotic section below). Indeed, a recent review indicated that the differences seen in caesarean-born infants may be due to factors beyond a lack of exposure to vaginal microbes (e.g. antibiotic usage), and other studies suggest the maternal gut microbiota (and cross-contamination and transfer during childbirth) may also play a key role in the establishment of these first microbes<sup>13,16</sup>.

Alongside transfer of members of the maternal vaginal and gut microbiota, other body sites such as the skin also harbour microbes that are typical members of the very early life infant gut, e.g. *Streptococcus* and *Staphylococcus*. However, after the first week, bacteria specialised in inhabiting the gut rapidly start to dominate<sup>17</sup>. The implications of this initial transient colonisation with bacteria originating from the vagina, mouth, and skin currently remain unclear but may link to establishment of an anaerobic environment by these typically facultative anaerobes (that use up the oxygen in the neonatal gut), which in turn facilitates colonisation by other more specialised (anaerobic) microbiota members. There is also evidence that strains of bacteria acquired from mothers are more likely to adapt to and persist in the infant gut than bacteria colonising from other sources<sup>17</sup>.

During early infancy, other close family members may also act as sources of bacterial colonisation of the infant gut, with these microbes acquired by horizontal transmission. A recent example of this from Japan has shown that a traditional Japanese custom of sharing bathtub water was linked to the transfer of *Bifidobacterium longum* between family members<sup>18</sup>. Interestingly, some common species of adult gut bacteria, including members of Clostridia and *Akkermansia muciniphila*, appear to be absent, or only present in low levels in the first year of life, and once established do not appear to originate from the mother<sup>19</sup>. Acquisition of these new microbes may be enabled by the ability among many microbiota members

(including Clostridia) to form protective endospores, allowing them to survive outside the gut for prolonged periods of time<sup>20</sup>.

Breast milk has been found to contain microbes and has recently emerged as another source of microbes for the infant gut. Suggested origins for the bacteria present in breast milk include external transfer into the milk ducts during feeding and internal transfer from the maternal gut to the breast. Many of the bacteria detected in milk samples were not found in the infant gut and *Bifidobacterium*, the most abundant bacteria in the infant gut, was found in only 40% of breast milk samples, suggesting that breast milk may act as an additional source of colonisation<sup>21</sup>. The importance of the milk microbiota remains to be explored, including the origin of these bacteria and other microbial groups, such as fungi, the presence of which has been recently reported in breast milk samples<sup>22</sup>.

The womb has traditionally been considered largely sterile; however, some previous studies detected microbial signatures after DNA sequencing of placenta, amniotic fluid, and meconium samples<sup>23</sup>. The inherent problems associated with sequencing low biomass samples like these that contain very low quantities of DNA are a matter of ongoing debate, with recent comprehensive carefully controlled studies indicating that all aspects of sample collection and preparation and downstream sequencing likely introduce contaminants observed in previous studies<sup>24</sup>. If indeed present, the low DNA yields indicate that any bacteria in the womb would be in very low numbers, with the various genus of bacteria identified not appearing to colonise the infant after birth. Thus, the effect of such bacterial exposure before birth is unlikely to form a key pathway for seeding of the neonatal gut microbiota.

Whilst these studies have shed some light on initial colonisation of the infant gut and microbial succession dynamics, there remains much to be uncovered as to the various routes of microbes into the infant gut. While research so far has focused on bacteria, there is an emerging world of viruses and fungi whose origin, transmission, and establishment in the gut remain unknown, including how these communities of microbes interact with each other during these very first ecological stages.

## Shaping the microbiota

### Human milk oligosaccharides

After colonising the infant gut, the composition of this new microbiota is shaped by diet and the components of that diet available to feed those bacteria present, i.e. breast milk or formula (or both). Breast milk is a complex biological fluid with many different nutritional and host components, such as enzymes and antibodies, and exclusive breastfeeding for up to 6 months is supported by WHO and UNICEF as the gold standard for infant nutrition<sup>25</sup>. Human milk oligosaccharides (HMOs) are chains of sugars found in human breast milk, and over 200 different types have been identified so far. They are not broken down by digestive enzymes produced by the infant and pass undigested into the infant’s lower intestine. HMOs have co-evolved to feed and encourage the establishment of beneficial species and strains of *Bifidobacterium* that produce

special enzymes to break down these complex sugars. They also signal to the cells lining the infant gut and act as decoys to which pathogenic bacteria attach, hampering their ability to colonise<sup>26</sup>. Owing to a strong bifidogenic effect, exclusive feeding with breast milk can bring the gut microbiota of caesarean-born infants closer to that of vaginal-born infants by selectively feeding the *Bifidobacterium* present<sup>27</sup>.

The HMOs in breast milk are synthesised in the mammary gland. Their amount and composition vary between women and over the course of lactation. HMO concentration is higher during the early stages of lactation and decreases gradually over time<sup>28</sup>. Differences between women are associated with the genetic status of the mother (i.e. linked to Lewis blood type [FUT3] and secretor status [FUC2]), and these differences in mothers' milk may support different bifidobacterial communities within the infant gut<sup>29</sup>. This raises questions for future research about whether different *Bifidobacterium* species and strains are better suited to particular maternal milk profiles.

*In vitro* studies have shown that HMOs promote the growth of certain, but not all, *Bifidobacterium*. The breakdown of HMOs is not a simple process of a specific HMO feeding a particular bacterial strain; recent research has shown that cross-feeding takes place within communities of different species and strains of *Bifidobacterium*<sup>30</sup>. Some strains can start the breakdown of these complex sugars and then others may make use of the by-products to fuel their own metabolism.

As understanding of the importance of HMOs in breast milk has increased, efforts have focused on synthesising individual HMOs, resulting in the production of two of the most common HMOs in milk: 2'fucosyllactose (2'FL) and lacto-N-neotetraose (LNnT). With the aim of adding one or two of these HMOs to infant formula (to bring it closer to human milk)<sup>31</sup>, the first formula milks containing 2'FL and LNnT have recently been trialled, funded by the formula producer Nestle, and were reported to be safe and have beneficial effects<sup>32</sup>. Other companies are now also actively moving into this rapidly emerging area of infant nutrition; however, one or two HMOs added to formula are unlikely to fully replicate the effects of the 200+ different HMOs identified so far in breast milk.

### Antibiotic treatment

While the infant diet feeds different bacteria in the infant gut, the treatment of infections with antibiotics shapes the infant microbiota by killing susceptible bacteria<sup>33</sup>. Before and during birth, maternal treatment with prophylactic antibiotics can also influence bacterial colonisation.

Antibiotic treatment prior to birth (in mothers) appears to alter infant microbiota composition. GBS is an important pathogen that can cause severe bacterial infections in young infants. To prevent transmission, mothers positive for GBS receive a preventative dose of antibiotics, called intrapartum antibiotic prophylaxis, before vaginal delivery to suppress the transfer of GBS to the infant. However, this practice exposes the infant to antibiotics through the umbilical cord and

has profound effects on the infant gut intestinal microbiota, diminishing beneficial commensals such as *Bifidobacterium* and increasing potential pathogenic bacteria such as *Escherichia* and *Enterococcus*<sup>34</sup>. Prophylactic antibiotics are also routinely used in caesarean section births to prevent infections, and this may also contribute to the differences in microbiota seen in caesarean-born infants. However, recent studies (controlling for such variables) indicate that caesarean section birth alone impacts the microbiota and potential subsequent immune programming<sup>35</sup> and that reduced *Bifidobacterium* was independent of prophylactic antibiotic exposure<sup>36</sup>. Such prophylactic antibiotics are necessary to prevent serious illness in infants; however, further work is required to understand the potential short- and longer-term impact on the infant microbiota.

### Preterm infants

Infants born prematurely before 37 weeks of gestation show important differences in the microbial colonisation of their gut due to their immaturely developed gut, antibiotic treatment, and neonatal intensive care hospital environment<sup>37</sup>. The gut microbiota of premature infants is characterised by potentially pathogenic types of bacteria that are commonly found in the hospital environment and low levels of *Bifidobacterium*. The transmission and establishment of a normal infant microbiota is disrupted by initial prophylactic antibiotic treatment, followed by often regular antibiotic treatments. In extremely premature infants, the gut itself may also be immature and less suitable for colonisation.

The abnormal microbiota common in premature infants and their underdeveloped gut and immune system leave them vulnerable to diseases such as necrotising enterocolitis (NEC) and sepsis, which are often caused by antimicrobial-resistant bacteria<sup>38,39</sup>. These rarely affect full-term infants but are serious and potentially fatal illnesses in premature infants. The prevention of NEC has encouraged efforts to "normalise" the premature infant microbiota, which include inoculating the infant gut with beneficial probiotic strains of bacteria and encouraging breastfeeding (supplemented with donor breast milk)<sup>40</sup>. Several clinical trial reviews indicate that providing probiotic bacteria to premature infants decreases NEC rates<sup>10,41,42</sup>. However, different species and strains of bacteria are available as potential probiotics to supplement infants, and as yet there is a lack of clear evidence or guidance as to which ones are most effective, either individually or in combination, and why some have failed to provide a benefit<sup>43</sup>. Understanding how to choose the right species and strain that can colonise the infant's gut and digest the food available (i.e. breast milk) is key to making probiotic treatments more effective in premature infants.

### Consequences of a disrupted early life microbiota

Several factors can disrupt the transfer and establishment of the infant microbiota, resulting in an abnormal microbiota composition, but whether these early microbial differences persist into later childhood is still unclear. However, as the early gut microbiota coincides with the immune priming window, with work indicating certain species and strains train and

mature the immune system, early differences may have long-term effects on future health<sup>44</sup>. The relative abundance of the bacterial genera has been reported to be decreased in the gut of infants at risk of asthma<sup>45</sup>. A recent review of the evidence found that overall in infants, greater levels of Bacteroidaceae, Clostridiaceae, and Enterobacteriaceae and lower levels of Bifidobacteriaceae and Lactobacillaceae were associated with higher occurrence of allergies, eczema, or asthma<sup>46</sup>. Although interesting, the observational nature of research linking early differences in infant gut microbiota to later health problems often does not account for potentially important confounding factors<sup>47</sup>. There may be other positive influences of the infant microbiota on immunity beyond just avoiding allergic problems. Associations between higher *Bifidobacterium* in early infancy and better immune system responses to vaccination, potentially enhancing immunologic memory, have been reported<sup>48</sup>. Working out which of these relationships are causal and how they can be manipulated to effectively prevent later-life health problems will require much more basic and translational research.

### Future research

Whilst bacteria have now been relatively well studied/profiled in the infant gut, there is much left to do with respect to understanding direct mechanisms governing microbe–microbe and microbe–host crosstalk. The additional microbial “dark matter”—the potentially large sections of the infant gut microbiota comprising fungi, viruses, and eukaryotic organisms—remains to be explored. Their presence, where they come from, and their effects in infants remain unknown. The use of faecal samples to explore infant gut microbiota is a limitation and is not necessarily representative of the sites of microbial colonisation higher up the infant gut, although access to these mucosal

sites is often extremely difficult in neonatal patients or almost impossible in healthy infants.

Areas of the world where the study of the infant gut microbiota has taken place may have masked how the microbiota is changing, and greater research and comparisons with infants in low- and middle-income country settings may give a broader picture. While *Lactobacillus* is not generally considered a component of the infant gut after the first week of life, research from India has found both its presence and its beneficial role in preventing sepsis when isolated and supplemented to infants<sup>49</sup>. Recent comparisons of infants from Indonesian and New Zealand infants showed that the bacterium *Bifidobacterium longum* subsp. *infantis* dominated the microbiota of Indonesian infants, while a different species, *Bifidobacterium longum* subsp. *longum*, dominated in New Zealand infants<sup>50</sup>. Moreover, variation in microbiota members and their components, e.g. *Bacteroides* and *Escherichia coli* lipopolysaccharide, may also lead to differential immune programming and subsequent risk of autoimmune conditions in childhood and later life<sup>51</sup>. Therefore, what is considered normal “here” may not be normal in other geographic regions of the world.

### Conclusions

The establishment of the gut microbiota in infants is an ecological succession shaped by sources of exposure to different microbes over time, which can be potentially disrupted by antibiotics, prematurity, delivery, and diet (Figure 1). The routes of vertical maternal transmission at birth and later acquisition from other sources need to be better understood in order to correct the disruption caused by necessary medical interventions.

## References



- Dzidic M, Boix-Amorós A, Selma-Royo M, et al.: **Gut Microbiota and Mucosal Immunity in the Neonate.** *Med Sci (Basel)*. 2018; 6(3): 56.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Henrick BM, Hutton AA, Palumbo MC, et al.: **Elevated Fecal pH Indicates a Profound Change in the Breastfed Infant Gut Microbiome Due to Reduction of *Bifidobacterium* over the Past Century.** *mSphere*. 2018; 3(2): e00041-18.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Ward TL, Knights D, Gale CA: **Infant fungal communities: Current knowledge and research opportunities.** *BMC Med*. 2017; 15(1): 30.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Maqsood R, Rodgers R, Rodriguez C, et al.: **Discordant transmission of bacteria and viruses from mothers to babies at birth.** *Microbiome*. 2019; 7(1): 156.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Khan Mirzaei M, Khan MAA, Ghosh P, et al.: **Bacteriophages Isolated from Stunted Children Can Regulate Gut Bacterial Communities in an Age-Specific Manner.** *Cell Host Microbe*. 2020; 27(2): 199-212.e5.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Lim ES, Zhou Y, Zhao G, et al.: **Early life dynamics of the human gut virome and bacterial microbiome in infants.** *Nat Med*. 2015; 21(10): 1228-34.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Reyes A, Blanton LV, Cao S, et al.: **Gut DNA viromes of Malawian twins discordant for severe acute malnutrition.** *Proc Natl Acad Sci U S A*. 2015; 112(38): 11941-6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Siqueira JD, Dominguez-Bello MG, Contreras M, et al.: **Complex virome in feces from Amerindian children in isolated Amazonian villages.** *Nat Commun*. 2018; 9(1): 4270.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Turrioni F, Milani C, Duranti S, et al.: **Bifidobacteria and the infant gut: An example of co-evolution and natural selection.** *Cell Mol Life Sci*. 2018; 75(1): 103-18.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Laursen MF, Sakanaka M, von Burg N, et al.: **Breastmilk-promoted bifidobacteria produce aromatic lactic acids in the infant gut.** *bioRxiv*. 2020.  
[Publisher Full Text](#)
- Yassour M, Jason E, Hogstrom LJ, et al.: **Strain-Level Analysis of Mother-to-Child Bacterial Transmission during the First Few Months of Life.** *Cell Host Microbe*. 2018; 24(1): 146-154.e4.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Perez-Muñoz ME, Arrieta MC, Ramer-Tait AE, et al.: **A critical assessment of the “sterile womb” and “in utero colonization” hypotheses: Implications for research on the pioneer infant microbiome.** *Microbiome*. 2017; 5(1): 243.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Shao Y, Forster SC, Tsalki E, et al.: **Stunted microbiota and opportunistic pathogen colonization in caesarean-section birth.** *Nature*. 2019; 574(7776): 117-21.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Stewart CJ, Ajami NJ, O'Brien JL, et al.: **Temporal development of the gut microbiome in early childhood from the TEDDY study.** *Nature*. 2018; 562(7728): 583-8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Dominguez-Bello MG, Costello EK, Contreras M, et al.: **Delivery mode**

- shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proc Natl Acad Sci U S A*. 2010; **107**(26): 11971–5. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
16. **F** Stinson LF, Payne MS, Keelan JA: **A Critical Review of the Bacterial Baptism Hypothesis and the Impact of Cesarean Delivery on the Infant Microbiome.** *Front Med (Lausanne)*. 2018; **5**: 109. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  17. **F** Ferretti P, Pasolli E, Tett A, *et al.*: **Mother-to-Infant Microbial Transmission from Different Body Sites Shapes the Developing Infant Gut Microbiome.** *Cell Host Microbe*. 2018; **24**(1): 133–145.e5. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  18. **F** Odamaki T, Bottacini F, Mitsuyama E, *et al.*: **Impact of a bathing tradition on shared gut microbes among Japanese families.** *Sci Rep*. 2019; **9**(1): e00036. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  19. **F** Korpela K, Costea P, Coelho LP, *et al.*: **Selective maternal seeding and environment shape the human gut microbiome.** *Genome Res*. 2018; **28**(4): 561–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  20. **F** Browne HP, Forster SC, Anonye BO, *et al.*: **Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation.** *Nature*. 2016; **533**(7604): 543–6. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  21. **F** Moossavi S, Azad MB: **Origins of human milk microbiota: New evidence and arising questions.** *Gut Microbes*. 2019; 1–10. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
  22. Boix-Amorós A, Martínez-Costa C, Querol A, *et al.*: **Multiple Approaches Detect the Presence of Fungi in Human Breastmilk Samples from Healthy Mothers.** *Sci Rep*. 2017; **7**(1): 13016. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  23. **F** Stinson LF, Boyce MC, Payne MS, *et al.*: **The Not-so-Sterile Womb: Evidence That the Human Fetus Is Exposed to Bacteria Prior to Birth.** *Front Microbiol*. 2019; **10**: 1124. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  24. **F** de Goffau MC, Lager S, Sovio U, *et al.*: **Human placenta has no microbiome but can contain potential pathogens.** *Nature*. 2019; **572**(7769): 329–34. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  25. UNICEF, WHO: **Capture the moment: early initiation of breastfeeding: the best start for every newborn.** 2018. [Reference Source](#)
  26. **F** McKeen S, Young W, Fraser K, *et al.*: **Glycan Utilisation and Function in the Microbiome of Weaning Infants.** *Microorganisms*. 2019; **7**(7): 190. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  27. **F** Liu Y, Qin S, Song Y, *et al.*: **The Perturbation of Infant Gut Microbiota Caused by Cesarean Delivery Is Partially Restored by Exclusive Breastfeeding.** *Front Microbiol*. 2019; **10**: 598. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  28. Akkerman R, Faas MM, de Vos P: **Non-digestible carbohydrates in infant formula as substitution for human milk oligosaccharide functions: Effects on microbiota and gut maturation.** *Crit Rev Food Sci Nutr*. 2019; **59**(9): 1486–97. [PubMed Abstract](#) | [Publisher Full Text](#)
  29. Kunz C, Meyer C, Collado MC, *et al.*: **Influence of Gestational Age, Secretor, and Lewis Blood Group Status on the Oligosaccharide Content of Human Milk.** *J Pediatr Gastroenterol Nutr*. 2017; **64**(5): 789–98. [PubMed Abstract](#) | [Publisher Full Text](#)
  30. Lawson MAE, O’Neill IJ, Kujawska M, *et al.*: **Breast milk-derived human milk oligosaccharides promote *Bifidobacterium* interactions within a single ecosystem.** *ISME J*. 2020; **14**(2): 635–48. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  31. **F** Vandenplas Y, Berger B, Carnielli VP, *et al.*: **Human Milk Oligosaccharides: 2’-Fucosyllactose (2’-FL) and Lacto-N-Neotetraose (LNnT) in Infant Formula.** *Nutrients*. 2018; **10**(9): 1161. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  32. Puccio G, Alliet P, Cajozzo C, *et al.*: **Effects of Infant Formula With Human Milk Oligosaccharides on Growth and Morbidity: A Randomized Multicenter Trial.** *J Pediatr Gastroenterol Nutr*. 2017; **64**(4): 624–31. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  33. Yassour M, Vatanen T, Silljander H, *et al.*: **Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability.** *Sci Transl Med*. 2016; **8**(343): 343ra81. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  34. **F** Zimmermann P, Curtis N: **Effect of intrapartum antibiotics on the intestinal microbiota of infants: A systematic review.** *Arch Dis Child Fetal Neonatal Ed*. 2020; **105**(2): 201–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
  35. **F** Wampach L, Heintz-Buschart A, Fritz JV, *et al.*: **Birth mode is associated with earliest strain-conferred gut microbiome functions and immunostimulatory potential.** *Nat Commun*. 2018; **9**(1): 5091. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  36. **F** Reyman M, van Houten MA, van Baarle D, *et al.*: **Impact of delivery mode-associated gut microbiota dynamics on health in the first year of life.** *Nat Commun*. 2019; **10**(1): 4997. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  37. **F** Henderickx JGE, Zwiitink RD, van Lingen RA, *et al.*: **The Preterm Gut Microbiota: An Inconspicuous Challenge in Nutritional Neonatal Care.** *Front Cell Infect Microbiol*. 2019; **9**: 85. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  38. Leggett RM, Alcon-Giner C, Heavens D, *et al.*: **Rapid MiniON profiling of preterm microbiota and antimicrobial-resistant pathogens.** *Nat Microbiol*. 2020; **5**(3): 430–42. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  39. **F** Pammi M, Cope J, Tarr PI, *et al.*: **Intestinal dysbiosis in preterm infants preceding necrotizing enterocolitis: A systematic review and meta-analysis.** *Microbiome*. 2017; **5**(1): 31. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  40. Alcon-Giner C, Dalby MJ, Caim S, *et al.*: **Microbiota supplementation with *Bifidobacterium* and *Lactobacillus* modifies the preterm infant gut microbiota and metabolome.** *Microbiology*. 2019. [Publisher Full Text](#)
  41. **F** AlFaleh K, Anabrees J: **Probiotics for prevention of necrotizing enterocolitis in preterm infants.** *Cochrane Database Syst Rev*. 2014; **4**: CD005496. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
  42. **F** Dermyshe E, Wang Y, Yan C, *et al.*: **The “Golden Age” of Probiotics: A Systematic Review and Meta-Analysis of Randomized and Observational Studies in Preterm Infants.** *Neonatology*. 2017; **112**(1): 9–23. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
  43. Costeloe K, Hardy P, Juszcak E, *et al.*: ***Bifidobacterium breve* BBG-001 in very preterm infants: A randomised controlled phase 3 trial.** *Lancet*. 2016; **387**(10019): 649–60. [PubMed Abstract](#) | [Publisher Full Text](#)
  44. **F** Renz H, Adkins BD, Bartfeld S, *et al.*: **The neonatal window of opportunity-early priming for life.** *J Allergy Clin Immunol*. 2018; **141**(4): 1212–4. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  45. **F** Arrieta MC, Stiemsma LT, Dimitriu PA, *et al.*: **Early infancy microbial and metabolic alterations affect risk of childhood asthma.** *Sci Transl Med*. 2015; **7**(307): 307ra152. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
  46. **F** Zimmermann P, Messina N, Mohn WW, *et al.*: **Association between the intestinal microbiota and allergic sensitization, eczema, and asthma: A systematic review.** *J Allergy Clin Immunol*. 2019; **143**(2): 467–85. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
  47. **F** Milliken S, Allen RM, Lamont RF: **The role of antimicrobial treatment during pregnancy on the neonatal gut microbiome and the development of atopy, asthma, allergy and obesity in childhood.** *Expert Opin Drug Saf*. 2019; **18**(3): 173–85. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
  48. **F** Huda MN, Ahmad SM, Alam MJ, *et al.*: ***Bifidobacterium* Abundance in Early Infancy and Vaccine Response at 2 Years of Age.** *Pediatrics*. 2019; **143**(2): e20181489. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  49. **F** Panigrahi P, Parida S, Nanda NC, *et al.*: **A randomized synbiotic trial to prevent sepsis among infants in rural India.** *Nature*. 2017; **548**(7668): 407–12. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
  50. **F** Lawley B, Ota A, Moloney-Geany K, *et al.*: **Fecal Microbiotas of Indonesian and New Zealand Children Differ in Complexity and *Bifidobacterium* Taxa during the First Year of Life.** *Appl Environ Microbiol*. 2019; **85**(19): e01105-19. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  51. **F** Vatanen T, Kostic AD, d’Hennezel E, *et al.*: **Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans.** *Cell*. 2016; **165**(4): 842–53. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

# Open Peer Review

Current Peer Review Status: 

---

## Editorial Note on the Review Process

F1000 Faculty Reviews are written by members of the prestigious F1000 Faculty. They are commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

---

## The reviewers who approved this article are:

### Version 1

1 **Omry Koren**

Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel

**Competing Interests:** No competing interests were disclosed.

2 **Susanne Brix Pedersen**

Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark

**Competing Interests:** No competing interests were disclosed.

3 **Avital Cher**

Department of Microbiology and Molecular Genetics, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

**Moran Yassour**

<sup>1</sup> Department of Microbiology and Molecular Genetics, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

<sup>2</sup> School of Computer Science & Engineering, The Hebrew University of Jerusalem, Jerusalem, Israel

**Competing Interests:** No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact [research@f1000.com](mailto:research@f1000.com)

F1000Research